Dr. Fatima Al-Hamlan, chair of the global health working group of the Civil Society 20

Dr. Fatima Al-Hamlan
Short Url
Updated 17 October 2020

Dr. Fatima Al-Hamlan, chair of the global health working group of the Civil Society 20

Dr. Fatima Al-Hamlan is chair of the global health working group of the Civil Society 20 (C20).

She is a scientist in the Infection and Immunity Department at King Faisal Specialist Hospital and Research Center in Riyadh, as well as an assistant professor at the College of Medicine at Alfaisal University in Riyadh.

Al-Hamlan joined the center as a post-doctorate fellow and global clinical scholar in June 2013, and remained in that position until March 2016. She became a research scientist and head of the Scientific Information Office in April that year.

Al-Hamlan’s focus is on conducting research into women’s health and promoting the health and well-being of Saudi females.

She was a founding member of the Riyadh-based Rofaida Women’s Health Organization in 2016 and is its vice president.

In 2007, Al-Hamlan received a master’s degree in population genetics from Washington State University. Five years later, she obtained a Ph.D. in microbiology, molecular biology and biochemistry from the University of Idaho. She also completed executive education courses at Harvard Business School and Harvard Medical School’s Leadership Program to further develop cross-functional skills, lead organizational change and inspire high-performing teams.

She has received awards for her scientific contributions in her field, including the Princess Nourah University’s Women Pioneers in Health Sciences Research Award in 2018.

Al-Hamlan is currently developing a network to advance women’s health, women in STEMM (Science, Technology, Engineering, Mathematics, and Medicine), and CSOs (Civil Society Organizations) within Saudi Arabia and globally.


Virus vaccine waiting on Saudi ‘green light’

A man works in a laboratory of Chinese vaccine maker Sinovac Biotech, developing an experimental coronavirus disease (COVID-19) vaccine, during a government-organized media tour in Beijing, China, September 24, 2020. (REUTERS)
Updated 24 min 56 sec ago

Virus vaccine waiting on Saudi ‘green light’

  • Health Ministry reports 398 new COVID-19 cases, 404 recoveries, 20 deaths

JEDDAH: China’s Sinovac coronavirus vaccine is set to be administered to Saudi patients after passing third stage clinical trials, but remains on hold until approved by the Saudi Food and Drug Authority.

King Abdullah International Medical Research Center (KAIMRC) signed an agreement with China’s Sinovac Biotech to receive a vaccine for COVID-19 to be distributed to about 7,000 health workers.
The vaccine has passed the third stage of trials at the King Abdullah Center for the National Guard.
“So far there have been no health complications or allergic reactions in those who have tried the vaccine, except for a fever or mild migraine, but that is normal when vaccination is administered with any virus,” said Aref Al-Amri, head of the Department of Biomolecules and Cytogenetics at the regional laboratory in Riyadh.

FASTFACTS

The total number of coronavirus cases in KSA reached 346,880.

The total number of recoveries in the Kingdom reached 333,409.

KAIMRC’s vaccine unit was among 10 global bodies chosen to test and evaluate several vaccines as part of an international alliance by the World Health Organization, CEPI and NIBSC.
Meanwhile, Saudi Arabia reported 20 new COVID-19-related deaths on Friday, raising the death toll to 5,383. There were 398 new cases reported in the Kingdom, meaning 346,880 people have contracted the disease. There are 8,088 active cases, 766 of which are in critical condition.
According to the Health Ministry, 53 of the newly recorded cases were in Riyadh, while Makkah recorded 32 and Jeddah 37. The ministry also announced that 404 more patients had recovered from the virus, bringing total recoveries in the Kingdom to 333,409.
There were 56,255 polymerase chain reaction tests conducted in the past day, bringing total test numbers to more than 8 million.